Your browser is no longer supported. Please, upgrade your browser.
NKTR Nektar Therapeutics monthly Stock Chart
NKTR [NASD]
Nektar Therapeutics
IndexS&P 500 P/E- EPS (ttm)-2.43 Insider Own0.60% Shs Outstand174.55M Perf Week0.20%
Market Cap3.52B Forward P/E- EPS next Y-2.50 Insider Trans-25.08% Shs Float173.96M Perf Month18.46%
Income-422.70M PEG- EPS next Q-0.74 Inst Own96.18% Short Float15.72% Perf Quarter-42.20%
Sales119.10M P/S29.53 EPS this Y289.50% Inst Trans13.64% Short Ratio10.17 Perf Half Y-37.36%
Book/sh8.92 P/B2.26 EPS next Y13.20% ROA-19.50% Target Price43.33 Perf Year-64.46%
Cash/sh8.68 P/C2.32 EPS next 5Y-7.30% ROE-25.20% 52W Range16.56 - 62.70 Perf YTD-38.70%
Dividend- P/FCF- EPS past 5Y36.30% ROI34.90% 52W High-67.86% Beta2.65
Dividend %- Quick Ratio14.00 Sales past 5Y51.60% Gross Margin80.90% 52W Low21.68% ATR0.94
Employees618 Current Ratio14.10 Sales Q/Q-97.90% Oper. Margin- RSI (14)46.78 Volatility4.85% 5.00%
OptionableYes Debt/Eq0.00 EPS Q/Q-111.80% Profit Margin- Rel Volume1.78 Prev Close20.22
ShortableYes LT Debt/Eq0.16 EarningsAug 08 AMC Payout- Avg Volume2.69M Price20.15
Recom2.20 SMA209.25% SMA50-15.06% SMA200-39.10% Volume4,797,246 Change-0.35%
Aug-09-19Downgrade Mizuho Buy → Neutral $79 → $21
Aug-09-19Downgrade JP Morgan Overweight → Neutral $62 → $33
Aug-09-19Downgrade Jefferies Buy → Hold $59 → $23
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-20-19 03:00PM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
11:00AM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics GlobeNewswire
09:55AM  NKTR, PS & BRFRF, BRFRY - Class Action - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
06:25AM  CLASS ACTION UPDATE: Brodsky & Smith, LLC Reminds Investors of Filing Deadline in Securities Fraud Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
Sep-19-19 03:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE
Sep-18-19 07:50PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm GlobeNewswire
09:55AM  NKTR, PS & BRFRF, BRFRY - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-17-19 09:07PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
07:21PM  Kessler Topaz Meltzer & Check, LLP Reminds Nektar Therapeutics Investors of Important Deadline in Securities Fraud Class Action Lawsuit GlobeNewswire
01:29PM  INVESTOR DEADLINES: Bernstein Liebhard LLP Reminds Investors in NKTR and GVA of Filing Deadlines GlobeNewswire
12:10PM  7 Stocks the Insiders Are Buying on Sale InvestorPlace
08:40AM  INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-16-19 04:25PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE +5.52%
09:54AM  NKTR, PS & BRFRF, BRFRY - Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
08:23AM  NKTR NOTICE, ROSEN, A TOP FIRM, Announces Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
Sep-13-19 03:05PM  Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics- NKTR ACCESSWIRE
03:00PM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
10:03AM  NKTR, PS & BRFRF, BRFRY - Class Action - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-12-19 06:23PM  ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action - NKTR GlobeNewswire
03:32PM  NKTR CLASS ACTION ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics PR Newswire
02:59PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Sep-11-19 06:13PM  Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors GlobeNewswire
10:02AM  NKTR, PS & BRFRF, BRFRY - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-10-19 08:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Canada Goose and Encourages Investors to Contact the Firm GlobeNewswire +11.48%
05:28PM  Wall Street Posts Losses on Tuesday GuruFocus.com
03:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE
10:20AM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:00AM  NKTR DEADLINE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
Sep-09-19 10:01AM  NKTR, PS & BRFRF, BRFRY - Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-07-19 09:30AM  Why Is Nektar (NKTR) Down 42.5% Since Last Earnings Report? Zacks
Sep-06-19 05:52PM  KESSLER TOPAZ MELTZER & CHECK, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against NEKTAR THERAPEUTICS NKTR GlobeNewswire
03:00PM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Update - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
09:58AM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Actions- Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-04-19 07:07PM  Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics Business Wire
07:01PM  Stocks the Market Is Discounting the Most This Summer GuruFocus.com
06:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
03:14PM  Here's Why Nektar Therapeutics Plummeted 38% in August Motley Fool
12:00PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Textron and Encourages Investors to Contact the Firm GlobeNewswire
10:30AM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-03-19 06:43PM  Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR PR Newswire
12:54PM  The 5 Worst Stocks So Far This Year Barrons.com
09:56AM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Aug-30-19 06:19PM  Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Nektar Therapeutics GlobeNewswire
06:00PM  ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics NKTR GlobeNewswire
06:00PM  LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm PR Newswire
03:00PM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Granite Construction Incorporated (GVA) Class Actions - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
10:43AM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Granite Construction Incorporated (GVA) Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
10:27AM  World's largest ad agency inks huge San Francisco office lease American City Business Journals
09:49AM  Why this biotech's new-school opioid is on hold with the FDA American City Business Journals
Aug-29-19 01:30PM  ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR PR Newswire
07:38AM  The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings Benzinga
Aug-28-19 09:42AM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Granite Construction Incorporated (GVA) Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
07:51AM  Should You Be Worried About Insider Transactions At Nektar Therapeutics (NASDAQ:NKTR)? Simply Wall St.
Aug-27-19 04:03PM  Stock Market in the Red on Tuesday GuruFocus.com
08:00AM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Granite Construction, Pluralsight, SAExploration, and Nektar and Encourages Investors to Contact the Firm GlobeNewswire
Aug-26-19 04:00PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics Business Wire
01:21PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics Business Wire
09:41AM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Granite Construction Incorporated (GVA) Class Actions - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Aug-25-19 03:06PM  The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day Weekend Benzinga
Aug-23-19 03:00PM  INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019 GlobeNewswire
10:55AM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Aug-22-19 07:30PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR) GlobeNewswire
03:00PM  INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019 PR Newswire
10:29AM  IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
09:59AM  INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019 ACCESSWIRE
Aug-21-19 04:52PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
04:35PM  NEKTAR THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Northern District of California against Nektar Therapeutics, Inc. GlobeNewswire
11:01AM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics NKTR Business Wire
Aug-20-19 08:00PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm PR Newswire
01:31PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR) Business Wire
Aug-19-19 09:43PM  Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR) Business Wire
Aug-15-19 08:35PM  Bragar Eagel & Squire, P.C. is Investigating Nektar Therapeutics, Inc. (NASDAQ: NKTR) on Behalf of Stockholders and Encourages Nektar Investors to Contact the Firm PR Newswire
05:22AM  Edited Transcript of NKTR earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-14-19 10:00AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nektar Therapeutics (NKTR) PR Newswire
Aug-13-19 03:06PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:44AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nektar Therapeutics (NKTR) ACCESSWIRE
Aug-12-19 02:20PM  Nektar Erases $1.8 Billion of Value on Doubts Over Its Cancer Drug Bloomberg -11.19%
12:29PM  Why Nektar Therapeutics Stock Is Falling Again Today Motley Fool
09:30AM  Nektar Therapeutics Drops Sharply for Second Day After Admitting Batch Issues TheStreet.com
08:23AM  3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences InvestorPlace
Aug-10-19 01:33PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Aug-09-19 06:30PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics Investors Business Wire -29.25%
04:35PM  Why Farfetch, Waitr Holdings, and Nektar Therapeutics Slumped Today Motley Fool
04:17PM  Biotech Crashes 29% After Bad Drug Likely Skewed Cancer Tests Investor's Business Daily
03:44PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics Investors Business Wire
03:13PM  Pharma companies Amarin, Nektar Therapeutics nosedive on product concerns Yahoo Finance Video
02:03PM  Large Option Trader Buying Nektar Calls Following Stock Crash Benzinga
01:33PM  Drugmakers Put Bad Spin on a Bizarre Week Bloomberg
12:56PM  Why Nektar Therapeutics Stock Is Crashing Today Motley Fool
11:58AM  Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud of Nektar Therapeutics PR Newswire
11:39AM  Biotech Investors Jolted Out of Summer Lull as High-Fliers Sink Bloomberg
11:11AM  Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss Zacks
08:59AM  Nektar Therapeutics Stock Is Plunging Because Theres No Shortage of Bad News Barrons.com
07:28AM  Nektar Therapeutics Sinks on Cancer Treatment Manufacturing Issues TheStreet.com
07:19AM  The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2 Benzinga
06:00AM  What You'll Want to Know About Nektar Therapeutics' Q2 Results Motley Fool
Aug-08-19 10:24PM  Nektar Therapeutics (NKTR) Q2 2019 Earnings Call Transcript Motley Fool
06:37PM  Nektar Therapeutics stock drops after results MarketWatch
06:11PM  Another Biotech Stock Halted As Manufacturing Issue Comes To Light Investor's Business Daily
05:45PM  Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates Zacks
Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc. Nektar Therapeutics also has a research collaboration with Trovagene, Inc. for the treatment of metastatic colorectal cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Labrucherie Gil MSVP & Chief Financial OfficerSep 16Option Exercise7.2125,000180,250177,872Sep 18 07:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerSep 16Sale20.5225,000513,000152,872Sep 18 07:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerSep 05Buy17.2815,000259,200107,668Sep 09 05:09 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 26Option Exercise16.3130,000489,300152,872Aug 27 05:20 PM
ROBIN HOWARD WPresident & CEOAug 23Option Exercise16.3130,000489,300312,775Aug 26 05:21 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale18.151,80932,833163,154Aug 19 07:09 PM
ROBIN HOWARD WPresident & CEOAug 16Sale18.1512,551227,801282,775Aug 19 07:08 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 16Sale18.155,06391,893122,872Aug 19 07:07 PM
Nicholson JohnSVP & Chief Operating OfficerAug 16Sale18.153,81969,315162,759Aug 19 07:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerAug 16Sale18.153,24558,89792,668Aug 19 07:06 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Option Exercise7.2125,000180,250152,935Aug 16 08:13 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Sale17.7925,000444,750127,935Aug 16 08:13 PM
ROBIN HOWARD WPresident & CEOJul 25Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 25Sale29.6533,333988,323295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Option Exercise7.2133,334240,338328,660Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Sale32.1133,3341,070,355295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Sale32.1033,3331,069,989295,326Jul 25 08:02 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Option Exercise7.2125,000180,250152,935Jul 12 06:31 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Sale34.5725,000864,250127,935Jul 12 06:31 PM
Lingnau LutzDirectorJul 08Option Exercise9.2410,00092,40033,200Jul 10 05:34 PM
Lingnau LutzDirectorJul 08Sale34.6310,000346,30023,200Jul 10 05:34 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Option Exercise7.2125,000180,250152,935Jun 19 05:50 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Sale33.7125,000842,750127,935Jun 19 05:50 PM
ROBIN HOWARD WPresident & CEOMay 23Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 23Sale32.6933,3331,089,656295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Option Exercise7.2133,334240,338328,660May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Sale33.3833,3341,112,689295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Sale32.9333,3331,097,656295,326May 23 07:19 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale31.371,92860,481164,463May 17 08:22 PM
ROBIN HOWARD WPresident & CEOMay 16Sale31.3713,383419,825295,326May 17 08:22 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale31.373,767118,171127,935May 17 08:20 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale31.374,077127,895166,578May 17 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale31.372,44976,82594,694May 17 08:19 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale31.373,461108,57295,913May 17 08:18 PM
GREER R SCOTTDirectorMar 08Option Exercise5.1410,00051,400145,083Mar 12 06:18 PM
ROBIN HOWARD WPresident & CEOFeb 21Option Exercise7.2133,333240,331342,042Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 21Sale41.0133,3331,366,986308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Option Exercise7.2133,334240,338342,043Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Sale43.2033,3341,440,029308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 19Option Exercise7.2133,333240,331350,924Feb 21 08:16 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 19Sale42.393,592152,265131,702Feb 21 08:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 19Sale42.392,386101,14397,143Feb 21 08:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 19Sale42.393,310140,31199,374Feb 21 08:13 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 19Sale42.391,80876,641166,391Feb 21 08:17 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 19Sale42.393,822162,015170,655Feb 21 08:15 PM
ROBIN HOWARD WPresident & CEOFeb 19Sale42.3342,2151,787,161308,709Feb 21 08:16 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Option Exercise10.6916,119172,312184,318Feb 06 07:17 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Sale42.1616,119679,577168,199Feb 06 07:17 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Option Exercise10.6963,000673,470237,477Jan 30 06:02 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Sale42.8263,0002,697,660174,477Jan 30 06:02 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale38.254,016153,612157,249Nov 19 06:15 PM
Nicholson JohnSVP & Chief Operating OfficerNov 16Sale38.255,982228,812174,477Nov 19 06:14 PM
ROBIN HOWARD WPresident & CEONov 16Sale38.2515,326586,220249,141Nov 19 06:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 16Sale38.254,694179,54681,029Nov 19 06:12 PM
Labrucherie Gil MSVP & Chief Financial OfficerNov 16Sale38.256,515249,199106,544Nov 19 06:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 16Sale38.254,524173,04378,734Nov 19 06:11 PM